share_log

B of A Securities Reinstates Buy on Acumen Pharmaceuticals, Announces $14 Price Target

Benzinga ·  Jul 20, 2023 06:52

B of A Securities analyst Geoff Meacham reinstates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and announces $14 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment